DNM1L and gastric cancer: The results indicated that higher DNM1L expression (HR = 2.420, 95% CI: 1.460–4.020, P = 0.001), ≥65 years (HR = 1.770, 95% CI: 1.070–2.930, P = 0.026), T3 and T4 stages (HR = 3.580, 95% CI: 1.810–7.070, P < 0.001), N2 and N3 stages (HR = 2.430, 95% CI: 1.440–4.110, P = 0.001), and M1 stage (HR = 8.230, 95% CI: 4.080–16.580, P < 0.001) were significantly associated with poor prognosis in patients with GC (Figure 3C).